GENE ONLINE|News &
Opinion
Blog

2026-06-19|

Tennessee Pharmacies Distribute High-Potency Ivermectin Promoted by Anti-Vaccination Physician

by GOAI
Share To

Pharmacies across Tennessee are currently distributing high-potency versions of the antiparasitic drug ivermectin, a practice spearheaded by a physician who publicly opposes vaccination and reports consuming large quantities of the medication himself. These pharmacies have established a market for the drug despite a lack of clinical evidence supporting its use for conditions beyond its FDA-approved applications.

The distribution efforts center on a medical professional who advocates for the drug’s use and claims to have ingested “bucketloads” of the substance. While ivermectin is traditionally used to treat parasitic infections, these specific Tennessee-based operations provide the drug in potent formulations to customers seeking it for off-label purposes. The pharmacies utilize specific business strategies to facilitate these sales, maintaining a steady supply chain for a product that remains a subject of significant medical and regulatory debate.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: June 19, 2026

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
LATEST
YEARS Diagnostic Algorithm Reduces CTPA Scans by Over 20 Percent in Cancer Patients
2026-07-12
West Nile and Usutu Viruses Detected in Wild Carnivore Populations in the Netherlands
2026-07-11
Norwegian Stakeholders Identify Implementation Challenges in Elder Abuse Prevention Guidelines for 2026 BMC Geriatrics Study
2026-07-11
Norwegian Stakeholders Identify Implementation Challenges in Elder Abuse Prevention Guidelines for 2026 BMC Geriatrics Study
2026-07-11
Biotech Stock Performance Gap Widens During Second Quarter of 2026
2026-07-11
PYGO2 Overexpression Linked to Increased Plasma Cell Proliferation in Multiple Myeloma Patients with 1q21 Amplification
2026-07-10
Sean Kaufman Faces Senate Scrutiny Over Past Vaccine Safety Comments Ahead of Confirmation Hearing
2026-07-10
Scroll to Top